Fundraising FoxHopewell Therapeutics
Woburn, US · Founded 2018 · Delaware corporation · 1 known investors
Find your way into Hopewell Therapeutics
Sign up to see every warm intro you have to Hopewell Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Hopewell Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
QX
Qiaobing XuNamed on SEC filing
Board
NS
Nan ShenBoard director
TV
Thomas V. Hennessey, IIIBoard director
XJ
Xutian JingBoard director
XF
Xiaowen FemgBoard director
CT
C. Thomas PaschallBoard director
Investors · 1
Hike CapitalreportedBeijing
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$25.9M disclosed across 5 rounds · 2020–2025
▶$2.5MraisedSep 2025 · 2 investors · BiotechnologyRule 506(b)
▶$2.5MraisedSep 2025 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Nan ShenDirector
- Qiaobing XuExecutive Officer, Director
- Thomas V. Hennessey, IIIDirector
- Xutian JingDirector
- Xiaowen FemgDirector
- C. Thomas PaschallDirector
- Offering amount
- $3.5M
- Amount sold
- $2.5M
- First sale
- Sep 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7.8MraisedMay 2024 · 8 investors · BiotechnologyRule 506(b)
▶$7.8MraisedMay 2024 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Thomas HennesseyDirector
- Nan ShenDirector
- Qiaobing XuExecutive Officer, Director
- Jake XiaDirector
- Xutian JingDirector
- Offering amount
- $10M
- Amount sold
- $7.8M
- First sale
- May 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7.1MraisedFeb 2022 · 4 investors · BiotechnologyRule 506(b)
▶$7.1MraisedFeb 2022 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- XUTIAN JINGDirector
- THOMAS V HENNESSEYDirector
- JAKE XIADirector
- QIAOBING XUExecutive Officer, Director
- HOWARD ROSENDirector
- Offering amount
- $7.1M
- Amount sold
- $7.1M
- First sale
- Jan 2022
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$8MraisedOct 2021 · 2 investors · BiotechnologyRule 506(b)
▶$8MraisedOct 2021 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Thomas V. HennesseyDirector
- Qiaobing XuExecutive Officer, Director
- Offering amount
- $8M
- Amount sold
- $8M
- First sale
- Sep 2021
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$500KraisedDec 2020 · 1 investors · BiotechnologyRule 506(b)
▶$500KraisedDec 2020 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Qiaobing XuExecutive Officer, Director
- Offering amount
- $500K
- Amount sold
- $500K
- First sale
- Dec 2020
- Incorporated
- Corporation, Massachusetts, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- Who are Hopewell Therapeutics's investors?
- Hopewell Therapeutics's investors include Hike Capital.
- How much funding has Hopewell Therapeutics raised?
- Hopewell Therapeutics has disclosed $25.9M raised across 5 rounds.
- Where is Hopewell Therapeutics headquartered?
- Hopewell Therapeutics is headquartered in Woburn, US.